Ascendis Pharma A/S
ASND
$157.71
-$3.81-2.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.53% | 21.33% | 27.68% | 16.30% | 7.35% |
| Total Depreciation and Amortization | -6.68% | -6.36% | -0.76% | 4.36% | 8.33% |
| Total Amortization of Deferred Charges | -4.27% | -4.27% | 14.61% | 14.61% | 14.61% |
| Total Other Non-Cash Items | -48.19% | 68.10% | 90.91% | 212.93% | 354.47% |
| Change in Net Operating Assets | 102.78% | -4.59% | 73.14% | -188.77% | -1,123.82% |
| Cash from Operations | 48.59% | 34.58% | 53.10% | 37.10% | 14.24% |
| Capital Expenditure | -22.09% | 41.54% | 84.34% | 81.85% | 86.10% |
| Sale of Property, Plant, and Equipment | 1,742.34% | 1,742.34% | 1,951.70% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -97.43% | -95.10% | -86.54% | -64.94% |
| Cash from Investing | -101.16% | -97.58% | -95.00% | -86.31% | -63.88% |
| Total Debt Issued | -1.54% | -1.54% | -6.55% | -- | 11,716.03% |
| Total Debt Repaid | -9.28% | -8.88% | -17.62% | -32.39% | -52.80% |
| Issuance of Common Stock | 1,024.07% | 3,209.62% | 2,708.56% | 355.30% | 346.56% |
| Repurchase of Common Stock | -1,488.96% | -- | -90,500.00% | -90,500.00% | -1,092.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 168.79% | 233.57% | 212.19% | 8,594.83% | 9,217.80% |
| Foreign Exchange rate Adjustments | 118.57% | 481.38% | 69.84% | 169.97% | -81.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 213.57% | 427.56% | 219.93% | 49.24% | 24.43% |